Beijing-headquartered AI medical firm Shukun Technology has secured 200 million yuan ($29 million) in a Series B2 round of funding led by Qiming Venture Partners, according to a statement.
This brings the total corpus raised by Shukun in its two tranches of Series B round to 400 million yuan ($58 million) over the past two months.
Shukun garnered $29 million in its Series B1 round from BOC International, Jianxing Medical Fund and return backers China Creation Ventures and Huagai Capital earlier in June this year.
China Creation Ventures, Huagai Capital, Morningside Venture Capital and Marathon Venture partners had infused nearly 200 million yuan ($29 million) in Shukun back in February 2019.
The latest round of funding saw the participation of new investors including software development player Thunder Software Technology, high-tech focused Everest VC and SPD Silicon Valley Bank.
Since its inception in 2017, the Beijing-based Shukun leverages AI technology such as machine learning aimed to offer novel imaging solutions for detection of cardiovascular disease, cancers and cerebral stroke.
Shukun will allocate the proceeds to facilitate the AI medical imaging business and expedite its global commercialisation.
CHINA DEAL MONITOR
DealStreetAsia has also put together a table listing out 30 prominent venture capital transactions in the Greater China region on August 24-31, 2020.
